學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Sanofi-Aventis's Tender Offer for Genzyme
內容大綱
This case is designed to be part of an MBA corporate finance class. In October 2010, Henri Termeer, the chairman and CEO of Genzyme (a top-five biotechnology company), received a letter from the CEO of Sanofi-Aventis (a large French pharmaceutical company) announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme given the number of promising new drugs in the company's pipeline and the success of its current drug portfolio. To estimate Genzyme's fundamental value, Termeer and his finance team would need to conduct a discounted cash flow (DCF) and other valuation analyses. Termeer needed to be well prepared for the board meeting during which the response to the offer would be formulated.